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Abstract
Although tumor-associated macrophages (TAMs) are involved in tumor growth and metastasis, the mechanisms controlling
their pro-tumoral activities remain largely unknown. The transcription factor c-MYC has been recently shown to regulate in
vitro human macrophage polarization and be expressed in macrophages infiltrating human tumors. In this study, we
exploited the predominant expression of LysM in myeloid cells to generate c-Mycfl/fl LysMcre/+ mice, which lack c-Myc in
macrophages, to investigate the role of macrophage c-MYC expression in cancer. Under steady-state conditions, immune
system parameters in c-Mycfl/fl LysMcre/+ mice appeared normal, including the abundance of different subsets of bone
marrow hematopoietic stem cells, precursors and circulating cells, macrophage density, and immune organ structure. In a
model of melanoma, however, TAMs lacking c-Myc displayed a delay in maturation and showed an attenuation of pro-
tumoral functions (e.g., reduced expression of VEGF, MMP9, and HIF1a) that was associated with impaired tissue remodeling
and angiogenesis and limited tumor growth in c-Mycfl/fl LysMcre/+ mice. Macrophage c-Myc deletion also diminished
fibrosarcoma growth. These data identify c-Myc as a positive regulator of the pro-tumoral program of TAMs and suggest c-
Myc inactivation as an attractive target for anti-cancer therapy.
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holds a Juan de la Cierva contract from the Spanish Ministry of Economy and Competition (MINECO). The CNIC is supported by the MINECO and the Pro-CNIC
Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vandres@cnic.es
. These authors contributed equally to this work.
Introduction
Macrophages, the mature form of peripheral blood monocytes
within tissues, are specialized phagocytic cells involved in multiple
processes, both in homeostasis and during the immune response
triggered by tissue damage or exposure to pathogens [1,2].
Tumor-associated macrophages (TAMs) produce factors that
promote angiogenesis and tumor cell proliferation, remodel tissue,
and dampen the immune response to tumors [3,4]. TAMs
consequently contribute to cancer progression and metastasis in
animal models and their density has been associated with poor
prognosis in a variety of human tumors, including breast, prostate,
bladder, lung and cervical carcinoma, glioma, lymphoma, and
melanoma [5,6,7]. In response to signals from the local
microenvironment, macrophages acquire distinct phenotypes that
polarize them toward a specific activation state [2,8,9]. For
example, activation with IFN-c, alone or in combination with
pathogen-derived signals such as LPS, leads to pro-inflammatory
or classically-activated macrophages, also referred to as M1
macrophages, which trigger pro-inflammatory type 1 immune
responses. Macrophage exposure to other immune signals results
in profoundly different functional phenotypes. These include
‘‘alternatively activated’’ or M2 macrophages, which develop as a
consequence of IL-4/IL-13 stimulation, and are associated with
type 2 immune responses. Moreover, a spectrum of phenotypes
related to anti-inflammatory processes, angiogenesis, and macro-
phage-regulated tissue repair is induced by a variety of stimuli,
including TGF-b, immune complexes, glucocorticoids and IL-10
[8,9,10]. Macrophages in tumors are confronted with diverse
different microenvironments, leading to the presence of TAM
subsets with specialized functions [11]. It has been postulated that
TAMs have a predominantly wound healing/regulatory pheno-
type, resembling that of alternatively activated M2 macrophages
[12]. Supporting this notion, TAMs exhibit high production of IL-
10 and low production of IL-12, thus suggesting a skewing of L-
arginine metabolism toward higher consumption by arginase-1
and lower consumption by iNOS, and deficient expression and
function of the transcriptions factors NF-kB and C/EBP, leading
to impaired iNOS gene expression and NO production [13,14].
However, recent studies demonstrated that TAMs also express
several M1-associated markers, probably reflecting the existence of
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TAM subpopulations with distinct functions and located in
different tumor regions [11].
Despite the profound effects of macrophage polarization and
activation on immune/inflammatory responses and tumor biology,
the molecular changes involved in rearranging the transcriptional
profile that controls the pro-tumoral phenotype of TAMs remain
largely unknown. Because deregulated expression of the proto-
oncogene c-Myc is associated with tumor development in mice and
humans, its role in tumor cell biology has been extensively
investigated [15]. c-MYC, which heterodimerizes with MAX to
activate expression of targets genes containing the E-box sequence
CACGTG in their promoter region [16,17], is also involved in
several processes in non-transformed cells, including cell growth
and apoptosis/survival [18]. Resting cells normally express low
levels of c-MYC, but expression of this immediate/early response
gene is dramatically increased upon exposure to growth factors
[19,20,21]. Moreover, c-MYC plays essential roles in hematopoi-
etic stem cell function and survival and in lymphoid compartment
homeostasis [22,23,24,25,26,27]. Recent evidence indicates that c-
MYC is induced in human macrophages during alternative
activation in vitro, and controls the expression of around 50% of
alternative-specific markers, suggesting a role in macrophage
polarization [28]. In addition, immunohistochemical analysis of
colon and breast tumor samples has identified c-MYC expression
in human TAMs [28].
To investigate the role of macrophage c-Myc expression in
tumor development, we exploited the predominant expression of
LysM in myeloid cells [29] to generate c-Mycfl/fl LysMcre/+ mice,
which lack c-Myc in macrophages. We investigated the develop-
ment of melanomas and fibrosarcomas in these animals and
characterized the properties of c-MYC deficient TAMs. Our
results demonstrate the therapeutic potential of c-Myc inhibition as
a way to curtail the pro-tumoral functions of TAMs and thereby
reduce cancer development.
Materials and Methods
Mice and Murine Macrophages
All animal procedures conformed to EU Directive 86/609/EEC
and Recommendation 2007/526/EC regarding the protection of
animals used for experimental and other scientific purposes, enacted
under Spanish law 1201/2005. All animal procedures have been
approved byTheCNICResearchEthicsCommittee (CertificatePA-
50/11). To generate mice with macrophage c-Myc deficiency, we
crossed c-Mycfl/fl mice[30]withLysMcre/+ mice[29] toobtain c-Mycfl/fl
LysMcre/+ mice (Mw-c-MycKO mice) and their c-Mycfl/fl littermates
(control). Bone marrow-derived macrophages (BMDMs) were
obtained by flushing mouse tibiae and femurs from control and
Mw-c-MycKO mice with ice-cold PBS and passing the suspension
throughacell strainerwitha70 mmcut-off.Cells (76106)wereseeded
in 100620 mm non-treated cell culture plates in 10 ml RPMI 1640
supplementedwith10%L929-cell conditionedmediumasasourceof
macrophage colony-stimulating factor (M-CSF) (American Type
Culture Collection CCL-1TM). Cultures were incubated at 37uC, 5%
CO2 for 7 days to obtain 95%-pure CD11b+ BMDMs. After this,
media were discarded and rinsed twice with saline solution.
Peritoneal macrophages were obtained from the peritoneal
cavities of mice, plated in cell culture dishes for 2 h and then
extensively washed to eliminate non-attached cells.
B16 Tumor Model and Tumor-cell–conditioned Medium
B16-F10 murine melanoma cells (a gift from Dr. Maria
Soengas, CNIO, Madrid) [31] were cultured in DMEM supple-
mented with 10% FCS, L-glutamine and penicillin/streptomycin.
Once grown to 90% confluence, medium was discarded, and flasks
were rinsed twice with saline solution. Cells were then incubated
with fresh complete medium for 24 h; the tumor-cell–conditioned
medium was collected, filtered (0.20 mm) and stored at 220uC. All
cell cultures were routinely checked for mycoplasma contamination.
For in vivo assays, mice were inoculated in the flanks with 56105
B16 melanoma cells previously infected with lentivirus encoding
the firefly luciferase gene [32]. JGA 95.1 murine fibrosarcoma cells
[33] were cultured in DMEM supplemented with 10% FCS, L-
glutamine and penicillin/streptomycin. For in vivo assays, 56105
JGA 95.1 cells were used to inoculate mouse flanks.
Macrophage-conditioned Medium
BMDMs were incubated with control medium or tumor-
conditioned medium for 24–48 h [28,34]. After this, medium was
discarded, culture plates were rinsed twice with saline solution,
and fresh medium was added for 24 h to obtain macrophage-
conditioned medium. The collected media were analyzed for
metalloproteinase activity in zymography assays [35] or used to
stimulate primary murine aortic endothelial cells (MAEC; a gift
from Dr. Carlos Zaragoza, CNIC, Madrid) [36] in proliferation
and wound healing assays. For proliferation assay, MAECS were
labeled with 5 mM CSFE (Sigma-Aldrich) for 5 min and then
cultured in macrophage-conditioned medium. MAEC prolifera-
tion was measured as the reduction of CFSE fluorescence intensity
after 24 h using a FACSCanto flow cytometer (BD Biosciences).
For wound healing assay, MAECs were grown to confluence in 6-
well tissue culture plates. A ‘‘wound’’ was made by scraping with a
P200 pipette tip across the center of the monolayer, and
macrophage-conditioned medium was added. Cell migration into
the denuded area was monitored by time-lapse photomicroscopy
and quantified with ImageJ software.
For CD8+ T proliferation/suppression assays, 26105 naive
BALB/c splenocytes were labeled with 5 mM CFSE, stimulated
with 1 mg/mL anti-CD3 to induce proliferation and cultured in
macrophage-conditioned medium. 24 h later CD8+ T cells were
labeled with anti-CD8-647 [11] and proliferation was measured as
the reduction of CFSE fluorescence intensity using a FACSCanto
flow cytometer (BD Biosciences).
Flow Cytometry and Cell Sorting
Cells were analyzed with a FACSCanto flow cytometer and
FACSDiva software (BD Biosciences). Viable cells were identi-
fied by propidium iodide exclusion. Singlet cells were discerned
with a stringent multiparametric gating strategy based on FSC
and SSC (pulse width and height). Cells were sorted on a
FACSAria flow cytometer (BD Biosciences). The following rat
anti-mouse antibodies were used for FACS analysis: Gr1-FITC
(53-5931), CD115-PE (12-1152), CD16/32-PE (12-0161),
CD117-PE (25-1171), CD34-Alexa 660 (50-0341), Sca1-FITC
(11-5981-85), Ly6G-FITC (551460), CD45-PE (12-0454-81)
from eBioscense; F4/80-Alexa 647 (MCA497A647), F4/80-
Alexa 488 (MCA497A488), MRC1-PE (MCA2235PE) from
Serotec; CD11b-PeCy7 (552850), CD8-APC (553035 BD),
CD4-Percpcy5.5 (550954), CD19-FITC (553785), SiglecF-PE
(552126) from BD Biosciences; CD45-biot (553078), biotin
mouse lineage (559971), CD11c-PE (553802), IL4Ra-PE
(552509) from BD Pharmingen; MHCII-PercpCy5.5 (107626)
from Biolegend; Ly6C-ALexa 647 (MCA2389A647) from BD
Biosciences.
RNA Isolation and Quantitative Real-time PCR (qPCR)
Total RNA was extracted with TRIzol reagent (Invitrogen) and
the miRNeasy mini kit (Qiagen), and was screened for purity and
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concentration in a Nanodrop-1000 Spectrophotometer (Thermo
Scientific). First-strand cDNA was synthesized from 2 mg total
RNA in a 25 ml reaction mixture using the High Capacity cDNA
Achieve kit (Applied Biosystems). The following gene-specific


















iNOS-Reverse: 59 TCCACAACTCGCTCCAAGATT 39.
Three replicates were performed for each experimental point,
and differences were assessed with a two-tailed Student’s t test.
Results were normalized using the housekeeping gene GAPDH
and the DD cycle threshold method, and are expressed in arbitrary
units.
Immunohistochemistry, Confocal Microscopy and Imaris
Analysis
Macrophage tumor infiltration was examined by immunohisto-
chemistry performed by a researcher blinded to genotype. After
sacrifice, tumor specimens were either frozen immediately after
surgical removal or fixed in buffered formalin and embedded in
paraffin. Macrophages were detected with a rat anti-CD68
monoclonal antibody (1/200 dilution, MCA1957, Serotec)
followed by anti-rat Alexa488-conjugated secondary antibodies
(A11006, A-11034, Invitrogen). c-MYC expression was analyzed
with rabbit anti-c-MYC polyclonal antibody (06-340, Millipore)
followed by Alexa635-conjugated anti-rabbit IgG antibody
(A21429, Invitrogen).
Macrophage proliferation in tumors was assessed by double
immunofluorescence with rabbit anti-Ki67 antibody (prediluted,
Clone SP6, MasterDiagnostica) together with rat anti-CD68
followed by Alexa635-conjugated anti-rabbit IgG antibody
(A21429 Invitrogen) and anti-rat Alexa488-conjugated secondary
antibodies (A11006, A-11034, Invitrogen). Macrophage apopto-
sis was measured with the In situ Cell Death detection kit
(Roche).
Cell nuclei were stained with TOPRO-3 (T3605, Invitrogen).
Slides were mounted with Slow-Fade Gold Antifade reagent
(S36936, Invitrogen) and images were acquired on a Leica TCS/
SP2 confocal microscope fitted with a 40X oil immersion
objective. Vessel coverage in tumors was assessed by quantification
of rabbit anti-CD31 (ab28364, Abcam) staining with Imaris
software in at least 3 tumors per genotype corrected for the
selected area.
In vivo Microscopy (IVIS) and Fluorescence Molecular
Tomography (FMT)
D-Luciferin (Sigma-Aldrich) was injected i.p. 15 min before
IVIS. IntegrinSense 750 and MMPSense 680 probes (Visen) were
injected i.v. 18 h before FMT. Mice were anesthetized with
isoflurane/oxygen mixture and then placed in an imaging cassette
(PerkinElmer/VisEn Medical). After positioning the cassette in the
FMT1500 imaging system (PerkinElmer/VisEn Medical), reflec-
tance images were captured in white light and fluorescence (2D
planar). For 3D imaging, a field around the tumor was selected,
and the tomographic scan was carried out. The scan data were
analyzed with the reconstruction software provided by the
manufacturer (PerkinElmer/VisEn Medical). For tomographic
data analysis, three-dimensional regions of interest (ROI) were
drawn around the tumor, and the total amount (in picomoles) of
fluorochrome was calculated with TrueQuant software (PerkinEl-
mer/VisEn Medical) using previously generated standards of the
appropriate dye.
Statistical Analysis
Results are expressed as mean6SD and were analyzed using
GraphPad-Prism (GraphPad Software, LaJolla, CA). Differences
were considered statistically significant at p,0.05, as determined
by unpaired 2-sided Student’s t test (experiments with two groups)
or two-way ANOVA followed by Bonferroni’s test (experiments
with more than two groups).
Results
Generation of Mw-c-Myc-KO Mice
Previous studies demonstrated the predominant expression of
LysM in the myeloid lineage [29]. Using this system, we crossed c-
Mycfl/fl mice [30] with LysMcre/+ [29] mice to generate Mw-c-Myc-
KO mice, in which c-Myc is deleted in macrophages, and control c-
Mycfl/fl littermates, in which c-Myc expression is intact. qPCR
confirmed significantly reduced levels of c-Myc in naı̈ve peritoneal
macrophages from Mw-c-Myc-KO mice compared with controls
(Fig. 1A), with no effect on total cell number (Fig. 1B) or
morphological characteristics in culture (data not shown). We
also found markedly lower c-Myc mRNA and c-MYC protein
levels in BMDMs obtained from Mw-c-Myc-KO mice (70–100%
reduction across all analyzed mice) (Fig. 1C), whereas expression
of n-Myc (Fig. 1D) and the macrophage-specific marker F4/80
were unaffected (data not shown). In contrast, c-Myc mRNA and
protein expression levels were normal in liver, kidney and testis
(Fig. 1E), non-immune tissues in which macrophages represent a
minor fraction. We next analyzed the proliferative capacity of Mw-
c-Myc-KO BMDMs upon stimulation with M-CSF [37]. Consistent
with previous reports that blockade of BMDM proliferation
correlates with decreased c-Myc expression [38,39], BrdU incor-
poration assays showed reduced de novo DNA synthesis in c-Myc-
deficient BMDMs (Fig. 1F).
Mw-c-Myc-KO Mice do not Exhibit Immune Alterations
Under Steady-state Conditions
In adult mammals, hematopoiesis takes place within the marrow
of large bones, and c-MYC is important for establishing the correct
balance between self-renewal and differentiation of hematopoietic
stem cells [22,25]. To test whether c-Myc inactivation affects
hematopoiesis in our model, we compared BM from control and
Mw-c-Myc-KO mice. Total BM cell counts were undistinguishable
between the two genotypes (Fig. 2A). Likewise, flow cytometry
analysis of distinct BM hematopoietic precursors by double Flk2/
CD90 immunostaining within the parental Lin2 Sca1+ c-Kit+
population (LSK) [40] revealed no differences in the levels of
multipotent progenitors (MPPs), long-term hematopoietic stem
cells (LT-HSCs) or short-term hematopoietic stem cells (ST-HSCs)
(Fig. 2B). Double immunostaining for CD16 and CD34 in the
c-Myc in Tumor-Associated Macrophages In Vivo
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LSK population [41] also showed no differences in the levels of
multiple erythroid progenitors (MEPs), granulocyte-macrophage
progenitors (GMPs) or common myeloid progenitors (CMPs).
Likewise, staining of the Lin2 population for CD115+ [42]
revealed no differences in the numbers of macrophage progenitors
(MPs) (Fig. 2B). Ex vivo functional analysis of BM from both
genotypes confirmed similar clonogenic potential of myeloid
precursors (Fig. 2C).
Hemogram analysis of circulating BM-derived cells showed no
significant differences between Mw-c-Myc-KO and control mice in
counts of total white blood cells, lymphocytes, myeloid cells,
granulocytes, red blood cells and platelets (Fig. 2D). The
phagocytic compartment was analyzed in further detail by flow
cytometry staining for Gr-1 and CD115 to identify neutrophils,
classical monocytes, and non-classical monocytes [43]. These
studies revealed no significant differences between the peripheral
blood profiles of Mw-c-Myc-KO and control mice (Fig. 2E).
Since macrophages are mature forms of peripheral blood
monocytes that infiltrate tissues [44], we studied their content in
immune organs under steady-state conditions. The two genotypes
showed similar tissue architecture and number and distribution of
macrophages in spleen (Fig. 2F) and in thymus and lymph nodes
(data not shown).
Reduced c-Myc Expression in Macrophages Attenuates
B16 Melanoma Tumor Growth without Affecting
Proliferation or Survival of TAMs
To investigate the effect of macrophage c-Myc deletion on
cancer, we used the B16 melanoma model, in which tumor growth
is critically dependent on the presence of TAMs [45]. B16
melanoma cells (56105) previously infected with lentivirus
carrying the firefly luciferase gene [32] were injected subcutane-
ously in the flanks of control and Mw-c-Myc-KO mice (2 tumors/
mouse). Bioluminescence in vivo imaging at successive intervals
after grafting revealed a significant upregulation of luciferase
intensity in control tumors at 12 days post-grafting that was absent
in tumors from Mw-c-Myc-KO mice (Fig. 3A). Consistent with
these findings, postmortem studies demonstrated a significant
reduction in tumor volume in Mw-c-Myc-KO mice compared with
control animals (Fig. 3B), and these differences occurred without
alterations in circulating B and T lymphocytes or CD11b+ cells
(neutrophils, eosinophils, and classical and non-classical mono-
Figure 1. Mw-c-Myc-KO mice exhibit reduced c-MYC expression in macrophages. (A) c-Myc mRNA expression determined by qPCR in
peritoneal macrophages from control and Mw-c-Myc-KO mice (n = 7 per genotype). (B) Total numbers of peritoneal macrophages isolated from
control and Mw-c-Myc-KO mice after washing the peritoneal cavity with 3 ml PBS (n = 8 mice per genotype). (C) Expression levels of c-Myc mRNA (top,
n = 6 per genotype) and c-MYC protein (bottom, representative blot) in BMDMs. (D) n-Myc mRNA expression determined by qPCR in BMDMs from
control and Mw-c-Myc-KO mice (n = 4 per genotype). (E) Expression levels of c-Myc mRNA (top) and protein analyzed by western blot (bottom) in liver,
kidney and testis (n = 3 control, n = 6 Mw-c-Myc-KO). (F) BMDM proliferation assessed by 59-bromodeoxyuridine (BrdU) incorporation (n = 3 per
genotype).
doi:10.1371/journal.pone.0045399.g001
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cytes) (Fig. 3C, D). As expected, examination of excised tumors
by double immunofluorescence revealed c-MYC expression in
TAMs from control mice, whereas it was undetectable in TAMs
from Mw-c-Myc-KO mice (Fig. 3E, left). Severely impaired c-Myc
expression in cells from Mw-c-Myc-KO mice was confirmed by
qPCR analysis of sorted TAMs (Fig. 3E, right). We also
performed double immunofluorescence experiments in TAMs to
evaluate proliferation (CD68+/Ki67+ co-expression, Fig. 3F) and
apoptosis (CD68+/TUNEL+ co-expression, Fig. 3G). These
studies demonstrated no differences in proliferative activity
(CD68+/Ki67+: 1.560.5% in control versus 1.460.6 in Mw-c-
Myc-KO) (Fig. 3F) or apoptotic cell death (CD68+/TUNEL+:
3.161.5% in control versus 3.660.9 in Mw-c-Myc-KO) (Fig. 3G).
Notably, we did observe differences between genotypes in the
Ki67 signal from CD68 negative cells, which are mostly tumor
cells (CD682/Ki67+: 4965.7% in control versus 30.663.3 in Mw-
c-Myc-KO).
Reduced c-Myc Expression in Macrophages Alters Tumor
T Cell Infiltration and TAM Phenotype
After sacrifice, tumors were dissociated and their immune
infiltrate analyzed by flow cytometry. Numbers of CD19+ B
lymphocytes were low in both genotypes and differences in the
percentage of CD45+ cells and CD4+ T lymphocytes did not reach
statistical significance (Fig. 4A and data not shown). In
contrast, tumors in Mw-c-Myc-KO mice contained significantly
lower numbers of myeloid CD11b+ cells and higher numbers of
CD8+ T cells (Fig. 4A). A more detailed analysis of tumor-
associated myeloid cells showed no significant differences in the
Figure 2. Characterization of the immune system of Mw-c-Myc-KO mice under steady-state conditions. All parameters were analysed in 6
mice per genotype. (A) Total numbers of bone marrow cells isolated from mice after flushing femurs and tibias with PBS. (B) Flow cytometry analysis
of bone marrow precursors. MMPs, LT-HSCs, ST-HSCs were analyzed by double immunostaining for Flk2 and Cd90 within the parental Lin2 Sca1+ c-
Kit+ (LSK) population. MEPs, GMPs and CMs were analyzed by double immunostaining for CD16 and CD34 within the parental LSK population. MPs
were detected by staining for CD115+ within the parental Lin2 population. (C) Clonogenic activity of total bone marrow cells. (D) Blood hemogram
analysis for the indicated cell types. (E) Flow cytometry of blood cells doubly stained for Gr-1 and CD115 to identify neutrophils (Gr-1highCD1152),
classical monocytes (Gr-1highCD115+) and non-classical monocytes (Gr-12CD115+). (F) Spleen sections were either stained with hematoxilin/eosin or
analyzed by confocal microscopy to visualize macrophage infiltration (CD68+ cells) and nuclei (DAPI staining). Representative images are shown, with
higher magnification for CD68 immunofluorescence showing macrophage-rich red pulp surrounding a spleenic follicle. The graph shows the
quantification of CD68+ macrophages within the spleen using Imaris software (n = 3 tumors per genotype).
doi:10.1371/journal.pone.0045399.g002
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relative abundance of neutrophils, eosinophils, Ly6ChighMHCIIneg
monocytes or dendritic cells between genotypes (Fig. 4B).
However, TAM subsets differed significantly, with more Ly6-
ChighMHCIIhigh TAMs and less Ly6ClowMHCIIhigh TAMs in
tumors from Mw-c-Myc-KO mice compared with controls
(Fig. 4B). Further characterization of the polarization status of
TAMs of both genotypes showed similar levels of the M2-like
markers MRC1 and IL4R but higher CD11c expression in Mw-c-
Myc-KO TAMs compared with controls (Fig. 4C).
Pro-tumoral Activity is Diminished in TAMs with Reduced
c-Myc Expression
The distinct proliferative and metastatic capacities of different
tumors were recently shown to be associated with the specific
pro-tumoral characteristics activities of the TAMs they contain
[11]. Moreover, different TAM subsets within a tumor have
been suggested to contribute differentially to tumor growth [11].
To investigate the impact of macrophage c-Myc deletion on the
pro-tumoral activity of TAMs, we sorted B16 melanoma tumor
cell suspensions and analyzed by qPCR the expression of three
factors required for tissue remodeling and angiogenesis in
cancer: hypoxia-inducible factor 1a (HIF1a), vascular endothe-
lial growth factor (VEGFA) and metalloproteinase-9 (MMP9).
Expression of these pro-tumor factors was significantly lower in
TAMs isolated from Mw-c-Myc-KO mice compared with controls
(Fig. 5A). Next, we performed non-invasive FMT of tumors
from mice injected with IntegrinSense 750 (Fig. 5B) and
MMPSense 680 (Fig. 5C) probes to detect angiogenesis and
metalloproteinase activity, respectively [46,47]. Consistent with
lower angiogenic activity and tissue remodeling, intensity of
both probes was lower in tumors from Mw-c-Myc-KO mice,
reaching statistically-significant differences for MMPSense
(Fig. 5B,C). Although these results might reflect in part the
bigger size of the tumors in control mice, expression of the
endothelial-cell–specific marker CD31 per area of tumor was
lower in tumors from Mw-c-Myc-KO mice (Fig. 5D).
To further investigate the role of c-MYC in the pro-tumoral
activities of TAMs, we exposed BMDMs to conditioned culture
medium from tumor cells (Fig. 6A), an in vitro model that
allows characterization of cell autonomous effects [28,34].
qPCR confirmed that control BMDMs exposed to tumor-cell–
conditioned medium expressed higher levels of c-Myc than Mw-
c-Myc-KO cells (Fig. 6B). Moreover, in line with our observa-
tions in TAMs, tumor-cell–conditioned medium induced Hif1a,
Figure 3. Mw-c-Myc-KO mice are resistant to growth of tumors derived from injected B16 melanoma cells. (A) B16 melanoma cells
expressing firefly luciferase were injected subcutaneously into both flanks of mice, and tumor growth was monitored over two weeks post-grafting
with the Xenogen IVIS 100 Bioluminescence in vivo imaging system (n = 6–8 tumors per genotype). (B) Tumor volume after sacrifice at two weeks
post-injection (n = 16 tumors per genotype). (C) Flow cytometry analysis for circulating CD11b+ myeloid cells, CD4+ T lymphocytes, CD8+ T
lymphocytes and CD19+ B lymphocytes in mice two weeks after tumor injection (n = 7, control; n = 8 Mw-c-Myc-KO). (D) Flow cytometry detection of
circulating myeloid cells two weeks after tumor injection (n = 7, control; n = 8, Mw-c-MYC-KO) (E) Representative confocal images showing double
immunofluorescence to visualize macrophages (CD68+ cells) and c-MYC expression in tumors, and quantification of c-Myc mRNA in TAMs isolated by
sorting tumor cell suspensions (n = 3 mice per genotype; two tumors pooled per mouse). (F) Representative confocal images and quantification of
proliferating TAMs (CD68+Ki67+) (n = 6 tumors per genotype). (G) Representative confocal images and quantification of apoptotic TAMs
(CD68+TUNEL+) (n = 6 tumors per genotype).
doi:10.1371/journal.pone.0045399.g003
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VefgA and Mmp9 expression in control but not in Mw-c-Myc-KO
BMDMs (Fig. 6C). Transcript levels of lactate dehydrogenase
(Ldh), which is a downstream target of c-MYC [48], was
strongly reduced in Mw-c-Myc-KO BMDMs (Fig. 6C). In
contrast, induction of the M1-like marker inducible nitric oxide
synthase (iNos) by tumoral medium was c-MYC independent
(Fig. 6C). The lower Mmp9 expression in Mw-c-Myc-KO
BMDMs correlated with lower metalloproteinase activity, as
revealed in zymogram assays (Fig. 6D). Moreover, whereas
culture supernatants from control BMDMs treated with tumor-
cell–conditioned medium promoted endothelial cell proliferation
and migration in wound healing assays, wound healing was
impaired in response to supernatants from similarly conditioned
Mw-c-Myc-KO BMDMs (Fig. 6E). Finally, culture supernatants
from Mw-c-Myc-KO BMDMs treated with tumor-cell–condi-
tioned medium showed lower ability to reduce CD8+ T-
lymphocyte proliferation (Fig. 6F). Together these results
highlight the role of c-MYC as a key positive regulator of the
pro-tumoral activity of mature TAMs.
Reduced c-Myc Expression in Macrophages Attenuates
Fibrosarcoma Tumor Growth
To assess whether c-Myc deletion in TAMs also affects the
growth of other tumor types, we implanted 56105 JGA 95.1
murine fibrosarcoma cells in the flanks of Mw-c-Myc-KO or control
mice (two grafts/mouse). Animals were sacrificed two weeks post-
grafting, and tumors were collected and analyzed. Confocal
microscopy confirmed that CD68+ macrophages from tumors of
control mice were positive for c-MYC, while c-MYC immunore-
activity was negligible in CD68+ cells from tumors grown in Mw-c-
Myc-KO mice (Fig. 7A). As in the B16 melanoma model,
fibrosarcomas in Mw-c-Myc-KO animals were significantly smaller
than those isolated from control mice (Fig. 7B). Similarly,
compared with controls, tumors from Mw-c-Myc-KO mice exhib-
ited a less developed vasculature (Fig. 7C).
Discussion
TAMs play a major role in establishing a microenvironment
able to support cancer development [12], but the molecular
mechanisms controlling the differentiation and activity of these
cells remain poorly characterized. It has been recently shown that
c-MYC regulates in vitro human macrophage polarization and is
expressed in macrophages infiltrating human tumors [28]. Possible
clinical application of these findings first requires validation of the
anti-tumor potential of targeting c-MYC function in TAMs in an
animal model. Here we report the generation and characterization
of Mw-c-Myc-KO mice, in which c-Myc expression is inhibited in
macrophages by using the loxP/LysM-Cre system [29]. Although
Figure 4. c-Myc deletion in macrophages affects T cell infiltration and the TAM phenotype in tumors. Flow cytometry analysis of single-
cell suspensions prepared from tumors obtained 17–25 days after injection of B16 cells (n = 11 control tumors; n = 9 Mw-c-Myc-KO tumors). (A) CD45+
immune cells were gated to identify the proportion of CD11b+ myeloid cells and CD4+ and CD8+ T lymphocytes. (B) The strategy shown on the left
was used to quantify distinct myeloid cell subsets in gated Cd11b+ Ly6G- cells. (n = 13 control tumors; n = 9 Mw-c-Myc-KO tumors) TADCs: tumor-
associated dendritic cells. (C) Analysis of CD11c, MRC1 and IL4R in TAMs (n = 6 control tumors; n = 7 Mw-c-Myc-KO tumors). Results are represented as
normalized DMFI (MFIab-MFIisotipe/MFIisotipe*100).
doi:10.1371/journal.pone.0045399.g004
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Mw-c-Myc-KO mice display no overt phenotypic changes under
steady-state conditions, they are protected from tumor develop-
ment in a graft model of B16 melanoma. Our studies demonstrate
that TAMs isolated from tumors in Mw-c-Myc-KO mice have
reduced expression of the key pro-oncogenic factors VEGFA,
HIF1a and MMP9. Remarkably, Mw-c-Myc-KO mice also show
defective tumor angiogenesis and reduced fibrosarcoma develop-
ment, suggesting that c-MYC expression in TAMs contributes to
the development of multiple tumor types.
Characterization of our model demonstrated that, under steady-
state conditions, c-MYC expression is strongly reduced in
peritoneal macrophages and BMDMs obtained from Mw-c-Myc-
KO mice, without affecting c-MYC expression in other tissues such
as kidney, liver or testis. Mw-c-Myc-KO mice exhibit normal BM
hematopoiesis, since no differences in hematopoietic precursors
could be detected by flow cytometry or clonogenic analysis
(including LSKs, LT-HSCs, ST-HSCs, MMPs, MEPs, CMPs,
GMPs and MPs). Consistent with the normal BM hematopoiesis,
Mw-c-Myc-KO mice have a normal content of immune cells in
peripheral blood and normal levels of macrophage infiltration in
immune organs.
To investigate tumor progression in control and Mw-c-Myc-KO
mice, we used the model of subcutaneous injection of B16
melanoma cells. In vivo luciferase bioluminescent assay and
postmortem analysis demonstrated reduced tumor growth in
Mw-c-Myc-KO mice. This indicates that c-Myc depletion in
macrophages critically affects their activation state, and conse-
quently their efficiency in promoting tumor growth, consistent
with recent reports that the differing abilities of tumors to
proliferate and metastazise correlate with the differing pro-tumoral
activities of associated TAMs [11,13,14].
Macrophages typically derive from circulating monoyctes and
several studies have shown that the different TAM subtypes may
originate from distinct monocyte precursors, including Ly6C-
Figure 5. TAMs isolated from Mw-c-Myc-KO mice show reduced pro-tumoral activity. B16 melanoma cells were injected into both flanks of
mice, and tumors were analyzed after 2 weeks. (A) Levels of pro-tumoral transcripts (VegfA, Mmp9, and Hif1a) in TAMs obtained by sorting single-cell
suspensions of tumors (n = 3 mice per genotype; two tumors pooled per mouse). (B) Representative FMT images of tumors after injecting
IntegrinSense 750 probe to monitor angiogenic activity in vivo. The graph shows quantification normalized to a standard volume of 1000 mm3 (n = 10
control tumors; n = 12 Mw-c-Myc-KO tumors). (C) Representative FMT images of tumors after injecting MMPSense 680 probe to monitor
metalloproteinase activity in vivo. The graph shows quantification normalized to a standard volume of 1000 mm3 (n = 10 control tumors; n = 12 Mw-c-
Myc-KO tumors). (D) Representative confocal images showing blood vessels (CD31+ endothelial cells). The graph shows quantification of CD31+ cells
per tumor area using Imaris software (n = 3 tumors per genotype).
doi:10.1371/journal.pone.0045399.g005
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Figure 6. In vitro analysis of the pro-tumoral behavior of macrophages from control and Mw-c-Myc-KO mice. (A) Strategy for studying
pro-tumoral behaviour of macrophages cultured in vitro in conditioned medium from control medium or tumor conditioned medium from B16
melanoma cells (n = 3 per genotype) (B) Expression levels of c-Myc mRNA in control and Mw-c-Myc-KO BMDMs treated with tumor-cell–conditioned
medium. (C) Transcript levels in BMDMs from both genotypes treated with control or tumor-cell–conditioned medium. (D) Top: Representative
zymography analysis of metalloproteinase activity in supernatants from BMDMs treated with control or tumor-cell–conditioned medium. Bottom:
Quantification of metalloproteinase activity determined by zymography analysis (n = 3 experiments). (E) Top: Quantification of endothelial cell
proliferation 24 h after stimulation with supernatant from BMDMs treated with control or tumor-cell–conditioned medium. Bottom: Quantification of
wound area 24 h after stimulation of scrape-damaged endothelial cultures with supernatant from BMDMs treated with control or tumor-cell–
conditioned medium. (F) Quantification of CD8-T lymphocyte proliferation 24 h after stimulation with supernatant from BMDMs treated with control
or tumor-cell–conditioned medium.
doi:10.1371/journal.pone.0045399.g006
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negative non-classical monocytes [49,50] and Ly6ChighMHCIIlow
classical monocytes [11,51]. It has been suggested that Ly6-
ChighMHCIIlow monocytes that infiltrate tumors first give rise to
Ly6ChighMHCIIhigh TAMs, which then differentiate into Ly6-
ClowMHCIIhigh TAMs [11]. We therefore analyzed the expression
of Ly6C and MHC in TAMs isolated from tumors that developed
in control and Mw-c-Myc-KO mice two weeks after B16 melanoma
cell injection. In control mice, we found a higher abundance of
Ly6ClowMHCIIhigh TAMs than Ly6ChighMHCIIhigh TAMs
(43.767.9 versus 17.165.3, p = 0.002, gated in CD11b+ cells).
In contrast, TAMs in Mw-c-Myc-KO mice displayed a delay in
maturation, as indicated by similar levels of Ly6ChighMHCIIhigh
and Ly6ClowMHCIIhigh subpopulations (28.4611.5% Ly6-
ChighMHCIIhigh versus 24.869.9% Ly6ClowMHCIIhigh, p = 0.13,
gated in CD11b+ cells). Since c-MYC activity in macrophages
contributes to the acquisition of the M2 phenotype [28], future
studies are warranted to assess whether differences in the
maturation state of macrophages resulting from c-Myc deficiency
affects other pathophysiological processes that are regulated by
M2 macrophages, such as parasite encapsulation, angiogenesis,
wound healing, fetus rejection, allergy and asthma.
The higher abundance of a less mature TAM population in Mw-
c-Myc-KO tumors could explain the decreased tumor development,
accounting for the impaired ability to promote cell proliferation,
an inability to block immune anti-tumoral responses, and reduced
production of pro-angiogenic molecules. In agreement with this,
the proliferation of CD68 negative cells within tumors was
diminished in Mw-c-Myc-KO mice compared with those from
control mice. Regarding the ability to counteract anti-tumoral
responses, we found higher CD8+ T-lymphocyte infiltration in
tumors from Mw-c-Myc-KO mice than in tumors in control mice.
This could be due, at least in part, to impaired capacity of Mw-c-
Myc-KO TAMs to inhibit CD8+ T-lymphocyte proliferation and to
a higher level of CD11c expression in Mw-c-Myc-KO TAMs, which
may have increased ability to interact with and stimulate CD8+ T-
lymphocytes.
Finally, we hypothesize that the TAM maturation state could
also modulate tumor growth through the differential production of
pro-tumoral molecules. Genetic deletion of c-Myc in the mouse
leads to embryonic death, in part due to vasculogenesis defects
caused by a failure of VEGF-dependent signaling [52,53].
However, c-Myc deletion in endothelial cells alone does not
prevent endothelial cell proliferation and vasculogenesis [54]
because vascular remodeling in tumor development is modulated
by TAMs [12]. Accordingly, we found that TAMs isolated from
Mw-c-Myc-KO tumors expressed reduced levels of the pro-
angiogenic molecules HIF1a, VEGFA and MMP9. In line with
in vivo findings, tumor-conditioned medium induced HIF1a,
VEGFA and MMP9 expression in control but not in Mw-c-Myc-
KO BMDMs, and wound healing assays showed impaired
proliferation and migration of endothelial cells treated with
supernatants from Mw-c-Myc-KO BMDMs exposed to tumor-
conditioned medium compared with controls with intact c-Myc.
We also found that this defect in pro-angiogenic molecules in
tumors from Mw-c-Myc-KO mice correlated with reduced devel-
opment of new blood vessels, as assessed through the postmortem
Figure 7. Mw-c-Myc-KO mice are resistant to fibrosarcoma growth and tumor angiogenesis. JGA 95.1 murine fibrosarcoma cells were
injected into both flanks of mice, and tumors were analyzed after 2 weeks. (A) Representative confocal double immunofluorescence images showing
macrophages (CD68+ cells) and c-MYC expressing cells in tumors (n = 3 tumors per genotype). (B) Postmortem tumor volume at two weeks post-
injection of fibrosarcoma cells (n = 6 control tumors; n = 5 Mw-c-Myc-KO tumors). (C) Representative confocal images showing blood vessels (CD31+
endothelial cells). The graph shows quantification of CD31+ cells per selected tumor area using Imaris software (n = 3 tumors per genotype).
doi:10.1371/journal.pone.0045399.g007
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analysis of tumors by confocal microscopy and in vivo FMT using
an Integrisense probe signal, which detects avb3 integrin positive
endothelial cells, a hallmark of neovascularization [55]. Support-
ing the impaired angiogenesis observed in postmortem analysis, in
vivo FMT analysis also revealed decreased MMPSense probe signal
in tumors from Mw-c-Myc-KO mice.
In summary, we have generated a new mouse model to
investigate the role of c-MYC macrophage expression on tumor
development. Characterization of this animal model in combina-
tion with in vitro studies identifies c-MYC as a positive regulator of
the pro-tumoral program elicited by TAMs, which is essential for
establishing a microenvironment that supports the growth of
melanoma and fibrosarcoma. We believe that our results
constitute a proof-of-concept that manipulating c-MYC expression
has therapeutic potential for cancer treatment.
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